

SCIENTIA MEETINGS

VACCINES SUMMIT-2022

October 11-13, 2022
Sheraton Reston Hotel, VA



PLATINUM SPONSOR

ThermoFisher
SCIENTIFIC

SILVER SPONSOR



EXHIBITORS



"image: Freepik.com". This cover page has been designed using images from Freepik.com



SCIENTIA MEETINGS

Website: <https://scientiameetings.com/conferences/vaccines/> | Ph: 1-815-595-8049 | Email: venky@sciresgroup.net

Get *Whova* for Vaccines Summit 2022

Official Event App

- Explore the **professional profiles** of event speakers and attendees
- Send **in-app messages** and **exchange contact info**
- **Network and find attendees** with common affiliations, educations, shared networks, and social profiles
- Receive **update notifications** from organizers
- Access the **event agenda**, GPS guidance, maps, and parking directions at your fingertips



Download Whova and take your event mobile.




Get Whova from the App Store or Google Play.

Please sign up for the app with your **social media account** or **email**

The event invitation code is:

ipi7w1mrql

You will be asked for an event invitation code after installing Whova



About Organizer:

Scientia Meetings understand the importance of networking and collaboration. Conferences are not just about discussion, but about sharing knowledge and research work, new ideas, and a lot of opportunities. We are launching events in the country to create real networking with scientists and researchers from research institutes, companies, laboratories, and government agencies. We aim to have our events with only a moderate number of invited guests/delegates attending related to discipline and to create a platform for conversations leading to opportunities according to their individual needs. Our aim is to provide a platform for research scholars, scientific leaders, and decision-makers to come together and share their research findings with other scientific professionals which help to improve the sharing of knowledge and easy access to scientific information.

We provide a unique opportunity to share your innovative ideas, evaluate your research works, and promote collaborative work through networking sessions for a brighter future.

About Vaccines Summit-2022:

Scientia Meetings invites participants across the globe to attend its second edition of Vaccines Summit which is going to take place during October 11-13, 2022, and is organized around the theme “next-generation vaccines treatment and diagnostics that save lives”, Vaccines Summit-2022 is comprised of various sessions designed to offer comprehensive symposiums that address current issues in the field of vaccine research and provides a fantastic opportunity to network with your peers from academia and industry.

Corporate Partnering: Vaccines Summit-2022 help commercialize your innovations and build your business development pipeline through corporate partnering. We will arrange a one-on-one partnering meeting on request. We will share the conference attendees list with you, a month before the conference and arrange for one-on-one meetings with selected corporate representatives.

How does this conference help young scientists? Vaccines Summit-2022 not only opens doors to your career, but also opens your eyes to future opportunities, new cultures, and international perspectives. With the majority of the students interested in doing higher studies abroad, the students’ marketing forum provides an opportunity for Postgraduate and Undergraduate students to have formal communication with University representatives from around the world. Postgraduate student recruitment is increasingly becoming a strategic priority for higher education institutions. Vaccines Summit-2022 provides an excellent networking opportunity for potential collaboration with businesses and organizations for students.

Investment opportunities: Industry prospectors are looking for breakthrough technologies that are ready for licensing, corporate partnering, or investment opportunities. This can include prototypes, demonstrations, and display booths to showcase your innovative solutions at Vaccines Summit-2022. Pitch your idea to an industrial expert jury to raise the capital you need to get started.

WE FOCUS ON THIS



At Novavax, we are focused on developing vaccines for diseases like COVID-19, SARS, and the seasonal flu—so your patients can focus on what matters most.



SO THEY CAN FOCUS ON THAT



Discover more at [KnowOurVax.com/future](https://www.knowourvax.com/future)
or call 1-844-NOVAVAX (1-844-668-2829)

Vaccines

Count on a partner who knows the way

mRNA vaccine and therapeutics workflow solutions

Scale-up solutions

Leverage tools, portfolios, and technical support to swiftly transition from product development and process optimization to commercial manufacturing


Quality

Seamlessly progress from preclinical development to commercial manufacturing and regulatory submission while following Good Manufacturing Practice (GMP) standards

Proven products

Our products are used to manufacture multiple clinical and commercial mRNA vaccines and therapeutics

Solutions to support every step of your vaccine development journey



Learn more at thermofisher.com/biotechvaccines



IMMUNITRACK

Transforming Precision Immunotherapies

NeoScreen

Most powerful MHC/epitope binding platform NeoScreen enabling prediction of T cell epitopes over large human and mouse MHC library with unmet accuracy.

- > Identifying critical T cell epitopes for next pandemic
- > Identifying shared and private tumor antigens

TCR-LA

Unique platform for development of novel generation of cancer therapeutics, namely TCR-Like Antibodies (TCR-LA).

- > Very stable and ultrapure MHC/epitope reagents
- > Unique off-target platform for specificity assessment



ONCOLOGY



VIRAL INFECTIONS

T Cell Epitope Target Discovery



TCR-LIKE ANTIBODIES



VACCINES

Read more about the NeoScreen Technology on our webpage
www.immunitrack.com/neoscreen-technology



Contact

Immunitrack ApS
Lersø Parkallé 42,
2100 Copenhagen Ø
CVR: 32347908

info@immunitrack.com
www.immunitrack.com

Immunitrack is founded upon world-leading research on MHC-epitope binding. Our proprietary epitope screening platform NeoScreen measures the affinity and stability of MHC/epitope interactions, with capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immuno-oncology, vaccine production, T cell therapies and immune monitoring.

Immunitrack's mission is to provide the pharmaceutical industry and research community with technology and reagents to select or redesign drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses.

CTL LAB●RATORIES^{LLC}

Monitoring T - and B - cell Immunity (CMI) for clinical trials

CTL Laboratories Offers Services to Meet Your Every Need:

- GCP-GLP- compliant testing; CLIA certified
- CMI and humoral assays for preclinical and clinical trials (Phase- I,- II, and -III)
- Processing whole blood to cryopreserved functional PBMC
- Assay Development tailored to your specific needs (e.g. ELISPOT, ELISA, NAb, CBA etc..)
- Assay Qualification/Validation



Cellular Technology Limited

20521 Chagrin Boulevard

Shaker Heights, OH 44122-5350

+1 216-325-7235 Phone • +1 216-791-8814 Fax

labservices@immunospot.com • www.immunospot.com

KEYNOTE PRESENTATIONS

ROOM-A

08:00-19:00 EST (Eastern Time Zone)

Session Chair: **Cyril Guyard**, BIOASTER

- 08:00-08:30 **The State of the Vaccine World**
Stanley Plotkin, Consultant and Emeritus Professor of the University of Pennsylvania, Vaxconsult, LLP
- 08:30-09:00 **Authorizing COVID-19 Vaccines for Children: When Do We Know Enough?**
Paul Offit, Children's Hospital of Philadelphia
- 09:00-09:30 **Pfizer COVID-19 Vaccine R&D: What Now? What Next?**
William C. Gruber, Pfizer Inc
- 09:30-10:00 **Nucleoside-modified mRNA LNP therapeutics**
Drew Weissman, Perelman School of Medicine, University of Pennsylvania
-
- 10:00-10:30 **Coffee Break**
-
- 10:30-11:00 **How to break the wheel: next generation vaccine strategies to end the cycle of pandemic threats before they start**
Kayvon Modjarrad, Pfizer Inc
- 11:00-11:30 **Vaccines for Viral Pandemics**
Dan Barouch, Beth Israel Deaconess Medical Center
- 11:30-12:00 **mRNA/adjuvant vaccines the best of both world?**
Cyril Guyard, BIOASTER
- 12:00-12:30 **Unlocking data science and technology to strengthen immunization and outbreak response**
Ruxandra Draghia-Akli, Johnson & Johnson
- 12:30-13:00 **Immune responses to vaccination with attenuated falciparum malaria: complex responses to a complex immunogen**
Kenneth D. Stuart, Seattle Children's Research Institute
-
- 13:00-14:00 **Lunch Break** Sponsored by 

Session Chair: **Adrian V.S. Hill**, The Jenner Institute, Nuffield Department of Medicine, University of Oxford

- 14:00-14:30 **Human monoclonal antibodies for emerging infections**
James E. Crowe, Jr., Vanderbilt Vaccine Center
- 14:30-15:00 **Moving away from the parenteral route: Development of BBV154, the first licensed intranasal SARS-CoV-2 vaccine**
Raches Ella, Bharat Biotech, India
- 15:00-15:30 **In vivo Nucleic Acid delivery for tailoring immunity and Immune therapy**
David Weiner, The Wistar Institute
- 15:30-16:00 **SARS-CoV2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron**
Alba Grifoni, La Jolla Institute for Immunology
-
- 16:00-16:30 **Coffee Break** Sponsored by 

- 16:30-17:00 **Facilitating the Development and Availability of COVID-19 Vaccines**
Peter Marks, Director, Center for Biologics Evaluation and Research, FDA
- 17:00-17:30 **SARS-CoV-2 vaccines: What happened, what have we learned, and what's next?**
Philip R Krause, Former FDA Deputy Director, Office of Vaccines Research and Review, and the Consultant to World Health Organization
- 17:30-18:00 **Chasing moving targets: Rapidly responding and evolving to combat emerging viral pathogens**
Robert H Carnahan, Vanderbilt University Medical Center

18:00-19:00 POSTER SESSION

- P-001 **Metabolic modulation of immune cells to enhance vaccine efficacy**
Ashima Shukla, Styx Biotechnologies Inc
- P-002 **Adjuvanted Virus-Mimicking Nanoparticle HIV Vaccine**
Xu Li, Zymeron Corporation
- P-003 **Development of an Exosome-based Pan Beta-Coronavirus Vaccine**
Zhilin Chen, Codiak Biosciences
- P-004 **Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSV Δ G-EBOV-GP)**
Vanessa Raabe, NYU Langone Health
- P-005 **Antigen presenting cell targeted T cell DNA vaccine candidate inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2**
Katarzyna Kuczkowska, Nykode Therapeutics ASA
- P-006 **Preclinical evaluation of a low-dose universal SARS-CoV-2 mRNA vaccine**
Huabin Zhu, ARV Technologies
- P-007 **Polysaccharide Activation with CDAPgreen, a New Water Soluble Cyanylating Reagent**
Andrew Lees, Fina Biosolutions
- P-008 **Carrier Proteins for Conjugate Vaccines**
Andrew Lees, Fina Biosolutions
- P-009 **Identification of Viral and Cancer epitopes using peptide:MHC Stability measurements**
Mie Linder Hübbe, Immunitrack ApS
- P-010 **Next generation saponin-based vaccine adjuvants**
Richard Guy, ImmunAdd Therapeutics
- P-011 **Highly Thermal Stable Nanoparticles of Recombinant Bivalent Vaccine Containing Spikes of SARS- CoV-2 Omicron and Delta Show High Immunogenicity and Offer Broad Cross-Protection**
Shengfeng Li, Bio-Thera Solutions, Ltd

18:00-19:00 RECEPTION

KEYNOTE PRESENTATIONS

ROOM-A

08:00-18:30 EST (Eastern Time Zone)

Session Chair: **Ralph S. Baric**, University of North Carolina

- 08:00-08:30 **Design and Testing of a Universal panSarsbecovirus Vaccine Candidate**
Ralph S. Baric, University of North Carolina
- 08:30-09:00 **Covax19/Spikogen®; the first full recombinant spike protein vaccine to obtain market authorization**
Nikolai Petrovsky, Flinders University, Australia, Research Director, Vaxine Pty Ltd
- 09:00-09:30 **CoVID vaccine responses after receipt of monoclonal Abs for prevention of COVID**
Mary Marovich, National Institutes of Health
- 09:30-10:00 **Development of a Multivariate Digital Biomarker of Vaccine-Induced Inflammation and its Relationship to Immunogenicity**
Steve Steinhubl, physIQ, Inc

10:00-10:30 **Coffee Break**

- 10:30-11:00 **COVID-19 vaccines based on a Newcastle disease virus (NDV) vector**
Peter Palese, Icahn School of Medicine at Mount Sinai
- 11:00-11:30 **Advancing a Broadly Protective Vaccine for the Prevention of Fungal Infections**
Karen A. Norris, University of Georgia
- 11:30-12:00 **Cancer vaccine triple synergistic combination immunotherapy for cancer**
Jay A. Berzofsky, Center for Cancer Research, National Cancer Institute
- 12:00-12:30 **Novel Strategies to Enhance Anti-Cancer Vaccine Outcome in Cancer Therapy**
Samir N. Khleif, Lombardi Comprehensive Cancer Center
- 12:30-13:00 **Personal dendritic cell vaccines for cancer and Covid-19**
Robert O. Dillman, AIVITA Biomedical, Inc.

13:00-14:00 **Lunch Break** Sponsored by Session Chair: **Siddappa Byrareddy**, University of Nebraska Medical Center

- 14:00-14:30 **A New Source of Cancer NeoAntigens as the Basis for a Broadly Preventative Cancer Vaccine**
Stephen Albert Johnston, Calviri, Inc
- 14:30-15:00 **Malaria Vaccine Development: A new era**
Adrian V.S. Hill, The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- 15:00-15:30 **Innovating to develop a highly effective malaria vaccine: From radiation to chemo to genetically attenuated PfSPZ produced initially in mosquitoes and then *in vitro***
Stephen L. Hoffman, Sanaria Inc.
- 15:30-16:00 **Intranasal Immunization: Device and Formulation Promises and Challenges**
Nektaria Karavas & Julie Suman, Aptar Pharma

16:00-16:30 **Coffee Break** Sponsored by 

- 16:30-17:00 **Challenges, opportunities, and the future of social listening to address misinformation**
Joe Smyser, The Public Good Projects (PGP)
- 17:00-17:30 **Parainfluenza Virus 5-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster Is Broadly Protective against SARS-CoV-2 Variants**
Biao He, CyanVac LLC
- 17:30-18:00 **Clinical Trial Phase I of Plant-based COVID-19 Vaccine in Thailand**
Waranyoo Phoolcharoen, Baiya Phytopharm Co. Ltd
- 18:00-18:30 **COVID-19 Vaccine and Mental Health**
Siddappa Byraredy, University of Nebraska Medical Center

Day-2**WEDNESDAY, OCTOBER 12, 2022****CORONAVIRUS (COVID-19) VACCINE RESEARCH****ROOM-B**

08:00-18:30 EST (Eastern Time Zone)

Session Chair: Daniela Weiskopf, La Jolla Institute for Immunology

- 08:00-08:20 **Can a sub-unit protein COVID-19 vaccine be a game-changer for the pandemic?**
Lila Estephan, Medigen Vaccine Biologics Corp
- 08:20-08:40 **Fc-dependent activities of antibodies against SARS-CoV-2**
Catarina E. Hioe, Icahn School of Medicine at Mount Sinai
- 08:40-09:00 **Humoral and cellular immune memory to four COVID-19 vaccines**
Daniela Weiskopf, La Jolla Institute for Immunology
- 09:00-09:20 **Design and Evaluation of MVA-Vectored Universal Beta coronavirus Vaccines**
Mark J. Newman, GeoVax
- 09:20-09:40 **COVID-19 Vaccine Registration Clinical Trials: "Building the Plane While Flying"**
Lisa M Dunkle, Novavax Inc
- 09:40-10:00 **Suboptimal COVID-19 mRNA Vaccination Protects Against SARS-CoV-2 Variants of Concern in the Absence of Neutralizing Antibodies and Correlates with Recall of Vaccine-Induced T-Cell Responses During Infection**
Michael Schotsaert, Icahn School of Medicine at Mount Sinai New York
-
- 10:00-10:30 **Coffee Break**
-
- 10:30-10:50 **A plant-based SARS-CoV-2 virus-like particle vaccine adjuvanted with AS03 induces a sustained polyfunctional IL-2 driven T cell response in humans**
Stephane Pillet, Medicago Inc
- 10:50-11:10 **Neutralization of SARS-CoV-2 Variants of Concern**
David C. Montefiori, Director, Laboratory for HIV and COVID-19 Vaccine Research & Development, Duke University Medical Center
- 11:10-11:30 **From broadly neutralizing antibodies to pan-betacoronavirus vaccines**
Raiees Andrabi, The Scripps Research Institute
- 11:30-11:50 **The global mRNA Vaccine Technology Hub – How a Vaccine Consortium in South Africa Can Meet the Mandate to Create Capacity and Capabilities in Low- and Middle-Income Countries Aimed at Improving the Lives of Millions of People Around the World**
Caryn Fenner, Afrigen Biologics (Pty) Limited Labs
- 11:50-12:10 **Evolution of Covid-like viruses under the influence of therapeutics**
Barbara A. Jones, IBM Research



12:10-12:30 **Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape**
Nash Rochman, NIH

12:30-12:50 **Oral Delivery of Vaccine Candidates Provides Protection Against Coronaviruses**
John Howard, Applied Biotechnology Institute

12:50-14:00 **Lunch Break** Sponsored by 

Session Chair: Kevin Saunders, Duke Human Vaccine Institute

14:00-14:20 **A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters**
Phanramphoei N. Frantz, National Center for Genetic Engineering and Biotechnology (BIOTEC) & Institut Pasteur

14:20-14:40 **Nanoparticle vaccination protects against multiple groups of beta coronaviruses**
Kevin Saunders, Duke Human Vaccine Institute

14:40-15:00 **An Exosome-Based Pan Beta Coronavirus vaccine**
Sriram Sathy, Codiak BioSciences

15:00-15:20 **Multiplexed vaccination against SARS-CoV-2 variants and pathogenic coronavirus species**
Sidi Chen, Yale School of Medicine

15:20-15:40 **Characterization of antibody epitopes in SARS-CoV-2 natural infection and vaccination and kinetics using Serum Epitope Repertoire Analysis (SERA)**
John Shon, Serimmune

15:40-16:00 **Tackling the pandemic using COVID-19 vaccines is a long way, only one step away, how to fix a knock at the door?**
Yang Xu, Secretary General of Global Immunity Surveillance Alliance

16:00-16:30 **Coffee Break** Sponsored by 

16:30-16:50 **SARS-CoV-2's unique cell tropism induces severe lung pathophysiology**
Masfique Mehedi, University of North Dakota

16:50-17:10 **Phase 1 Safety Findings, Pharmacokinetics, and Nebulization Stability of IN-006 Support its Development as a Potent, Dose-Sparing Inhaled Antibody Therapy for COVID-19**
Samuel Lai, University of North Carolina at Chapel Hill

17:10-17:30 **Collection of SARS CoV-2 Serum and Secretions for Countermeasure Development in New Orleans, LA**
Dahlene Fusco, Tulane University

17:30-17:50 **SARS Co-V-2 immunological responses in a real-life cohort at an academic research center**
Marcel Curlin, Oregon Health and Sciences University

17:50-18:10 **Diverse perspectives of the COVID-19 vaccines and vaccination drive: analysis of social media discourse and interviews with staff and students at a university hospital**
Oluchi Mbamalu, University of Cape Town

18:10-18:30 **COVAXIN: A whole SARS-CoV-2 virion inactivated vaccine against COVID-19**
Robert J. Hopkins, Ocugen, Inc.

ORAL PRESENTATIONS

ROOM-A

08:00-16:30 EST (Eastern Time Zone)

Session Chair: **David J. Dowling**, Boston Children's Hospital and Harvard Medical School

- 08:00-08:20 **Needle-free: Improved vaccine performance without the jab**
Paul LaBarre, PharmaJet
- 08:20-08:40 **Identifying Potentially Effective Strategies for Incorporating the Novel Complement Peptide-Derived Immunostimulant CPDI-02 with Nanoscale Dosage Forms for Mucosal Vaccines: An Update**
Joseph A. Vetro, University of Nebraska Medical Center
- 08:40-09:00 **Adjuvanted Vaccines Targeted to Vulnerable Populations**
David J. Dowling, Boston Children's Hospital and Harvard Medical School
- 09:00-09:20 **mRNA vaccines against emerging viral infections**
Alexander Bukreyev, University of Texas Medical Branch
- 09:20-09:40 **A cell-culture model of neoplasia that can be applied to study the biology of spontaneously transformed cells**
Andrew M. Lewis, Office of Vaccines Research and Review
- 09:40-10:00 **Liposome-Display of Antigens: A Versatile Approach for Vaccine Development**
Jonathan F. Lovell, University of New York at Buffalo
-
- 10:00-10:30 **Coffee Break**
-
- 10:30-10:50 **Whole-cell Vaccine Candidates Induce a Protective Response Against Virulent *Acinetobacter baumannii***
Stephen J. Dollery, Biological Mimetics, Inc.,
- 10:50-11:10 **Vaccines and monoclonal antibodies to counteract opioid use disorders and drug overdoses**
Marco Pravettoni, University of Washington School of Medicine
- 11:10-11:30 **A VLP-Forming HIV-1 *env-gag* mRNA Vaccine Platform**
Paolo Lusso, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- 11:30-11:50 **Strong Immunogenicity of Conserved Mosaic T-cell Vaccines HIV consvX in HIV-negative Subjects in the UK and Africa**
Tomas Hanke, University of Oxford
- 11:50-12:10 **Influenza vaccines for newborns: Can we increase protection in this vulnerable population?**
Martha Alexander-Miller, Wake Forest School of Medicine
- 12:10-12:30 **Alleviation of COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants**
Yongjun Sui, National Cancer Institute
- 12:30-12:50 **Lessons from The Vaccination Demand Observatory, a global effort to increase vaccine demand**
Savannah Knell, The Public Good Projects (PGP)

12:50-14:00 **Lunch Break** Sponsored by **ThermoFisher SCIENTIFIC**

Session Chair: **Andrew Lees**, Fina Biosolutions LLC

- 14:00-14:20 **Nucleic Acid-Based UNITE® Vaccine Platform Provides Novel Treatment Options for Unmet Medical Needs in Oncology, Allergy and Infectious Diseases**
Wei Shen, Immunomic Therapeutics
- 14:20-14:40 **A Novel Ultrasensitive Cell-Free SARS-CoV-2 Neutralizing Antibody Assay for Measuring Humoral Immune Response of Vaccine with High Lab-To-Lab Consistency**
Feng Xuan, SpearBio Inc
- 14:40-15:00 **Intranasal vaccine for Lyme disease**
Maria Gomes Solecki, The University of Tennessee Health Science Center
- 15:00-15:20 ***E. coli* Expressed Carrier proteins for Conjugate Vaccines: EcoCRM®(CRM197), 8MTT (tetanus toxin), Q(virus-like-particle)**
Andrew Lees, Fina Biosolutions LLC
- 15:20-15:40 **Incorporating Molecular Dynamic Modeling to Predict T Cell Epitopes for Vaccine Design**
Karen S. Anderson, Arizona State University
- 15:40-16:00 **Preclinical evaluation of a low-dose universal SARS-CoV-2 mRNA vaccine**
Renhuan Xu, ARV Technologies

16:00-16:30 **Coffee Break** Sponsored by



Day-3

WEDNESDAY, OCTOBER 13, 2022

NEW VACCINE DEVELOPMENT

ROOM-B

08:00-16:30 EST (Eastern Time Zone)

Session Chair: **Mark Connors**, National Institute of Health

- 08:00-08:20 **Malaria vaccines for pregnant women: Creating a path and a pipeline**
Patrick E. Duffy, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- 08:20-08:40 **EBV: Do we know enough to advocate prophylactic vaccination?**
Baochun Zhang, Dana-Farber Cancer Institute; Harvard Medical School
- 08:40-09:00 **Polymer based delivery platform for Protein and mRNA vaccines**
Madhavan Nallani, ACM Biolabs Pte Ltd
- 09:00-09:20 **Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in US Population**
Denise L Faustman, Harvard Medical School
- 09:20-09:40 **Vaccination against recurrent skin and soft tissue infection caused by *Staphylococcus aureus***
M. Javad Aman, Integrated Biotherapeutics, Inc.
- 09:40-10:00 **NIAID Preclinical Services Facilitate ZIKV Vaccine Product Development by Evaluating the Comparability of Neutralizing Antibody Assays for Predicting Vaccine Effectiveness**
Janet Lathey, DMID/NIAID/NIH
- 10:00-10:30 **Coffee Break**
- 10:30-10:50 **Protective efficacy of purified inactivated Zika virus (ZPIV) vaccine against ZIKV infection during pregnancy in mice and common marmosets**
In-Jeong Kim, Trudeau Institute

- 10:50-11:10 **The Impact of Prior Flavivirus Experience on Zika Vaccination**
Shelly J. Krebs, Emerging Infectious Disease Branch (EIDB), Walter Reed Army Institute of Research (WRAIR)
- 11:10-11:30 **Towards and AI Model of the Human Immunome**
Theodore (Ted) Schenkelberg, Human Vaccines Project
- 11:30-11:50 **Antiviral Vaccine Route and Form Potently Impact Immunogenicity and Efficacy**
Mark Connors, National Institute of Health
- 11:50-12:10 **Structure and immunogenicity of a prefusion-stabilized Nipah virus fusion protein**
Patrick O. Byrne, The University of Texas at Austin
- 12:10-12:30 **Vaccine Acceleration by Modular Progression (VAMP): Delivering Safe and Effective Vaccines to the Warfighter against New and Emerging Threats**
LTC Amanda Love, Joint Product Manager for the Botulinum/Plague Vaccine Development program, JPM CBRN Medical
- 12:30-12:50 **NYVAC-KC, A Replication Competent, Highly Attenuated Vaccinia Virus Vaccine Vector**
Bert Jacobs, Arizona State University School of Life Sciences
-
- 12:50-14:00 **Lunch Break** Sponsored by 
-
- 14:00-14:20 **A Novel PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) shows potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models**
Pravin T. P Kaumaya, Ohio Innovation Exchange
- 14:20-14:40 **Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults**
Susan M Bueno, Pontificia Universidad Catylica de Chile
- 14:40-15:00 **Inactivated vaccine-induced SARS-CoV-2 variant-specific immunity in children**
Alexis M Kalergis, Pontificia Universidad Catylica de Chile
- 15:00-15:20 **Identification of Viral and Cancer epitopes using peptide: MHC Stability measurements**
Olivia Lie-Andersen, Immunitrack ApS
- 15:20-15:40 **The Positive Effect of Venom Immunotherapy-VIT on other Allergies**
Leonora HANA-LLESHI, Allergist-immunologist, Gjakova, KOSOVO
-
- 15:40-16:30 **Coffee Break** Sponsored by 
-